Recent Company News

• 01:02 AM ET Aug 21, 2026
  

  Ipsen completes acquisition of Kartos Therapeutics; deal was announced 29-Jun (€163.40, 0.00)

• 06:13 AM ET Aug 20, 2026
  

  China's NMPA to include Ipsen's Iqirvo in priority review list for adults who do not respond well to UDCA alone, or used by itself for patients who cannot tolerate UDCA (€165.30, +0.20)

• 04:42 AM ET Jul 30, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 01:03 AM ET Aug 03, 2026
  

  Ipsen transferred underperform at Jefferies; prior rating was hold (€167.20, 0.00)

• 11:16 AM ET Jul 30, 2026
  

  Transcript Intelligence: Ipsen Q2 Earnings Guidance

• 11:16 AM ET Jul 30, 2026
  

  Transcript Intelligence: Ipsen Q2 Earnings Themes

• 11:16 AM ET Jul 30, 2026
  

  Transcript Intelligence: Ipsen Q2 Earnings Q&A

• 03:27 AM ET Jul 30, 2026
  

  StreetAccount Metrics Recap - Ipsen Q2 Earnings (€165.05, +1.35)

• 02:59 AM ET Jul 30, 2026
  

  StreetAccount Summary - European pre-market trading update